Introduction
Today’s pharmaceutical landscape requires a more dynamic, multidimensional approach to understanding the drivers of brand utilization. As stakeholder networks become increasingly complex and the industry shifts toward specialty, regimen-based therapies, traditional Attitude, Trial, and Usage (ATU) research, built primarily around one stakeholder’s viewpoints, is no longer sufficient. Integrating secondary data with primary research, primarily through a “Secondary First” philosophy, is transforming how organizations generate, interpret, and act on insights to guide brand strategy and commercial execution.
The Evolution of Brand Utilization Research
From Siloed Tracks to Integrated Approaches
- Traditional ATU: Focuses on surveying select healthcare professionals (HCPs) to capture perceptions, intentions, and behaviors, often missing the context provided by patient, payer, and other stakeholder data
- Secondary First & Integrated ATU: Leverages robust secondary data sets (claims, EHRs, payer records, promotion data) to anchor and refine primary research, aligning all available insights for a richer, more actionable understanding of marketplace realities
Why Integrated Approaches Outperform Standalone Solutions
The Power of Secondary Data
- Granularity and Scale: Access to anonymized, patient-level datasets, payer claims, and real-world promotion touchpoints uncovers patterns across tens of thousands of prescribers and hundreds of thousands of patients, going far beyond the reach of even well-designed surveys
- Contextualization: Secondary data confirms whether HCP perceptions (e.g., about managed care access) reflect systemic market realities or practice-specific phenomena
- Segmentation and Targeting: Enables precise identification of high-potential yet underutilized prescribers, as well as local market anomalies, so primary research focuses on the “why” for targeted segments.
The Critical Role of Primary Research
- Root Cause Uncovering: Surveys and interviews probe motivations, beliefs, and attitudes that drive observed patterns, explaining why actions, preferences, or gaps exist and surfacing psychographic drivers behind prescribing behavior
- Validation and Expansion: Hypotheses derived from secondary data are tested, refined, and expanded, ensuring research is both relevant and efficient.
Key Components of an Integrated ATU Model
| Component | How Secondary Data Adds Value | How Primary Research Adds Value | Example Use |
|---|---|---|---|
| Prescribing Behavior | Reveals actual patient flows, switches | Explores reasons for switches or stagnation | Identify HCPs whose patients don’t persist and probe root causes in survey/interview |
| Patient Characteristics | Profiles demographics, co-morbidities | Explains influence of these factors in HCP choices | Link EHR comorbidity data to HCPs choosing differently for similar patients |
| Impact of Promotion | Measures correlation of messages and Rx | Gauges message recall, attitude shifts | Assess why certain messages improve utilization only for specific HCPs or patient segments |
| Market Access | Shows true co-pay, plan barriers | Reveals perceived vs. actual obstacles | Determine if access issues are widespread or practice-specific |
| Competitor Analysis | Maps competitor penetration and loyalty | Probes motivations for preferring alternatives | Integrate claims data to track switching and explore underlying beliefs |
| Future Intentions | Projects trends from behavior data | Reveals drivers of intended usage increase/decrease | Forecast utilization based on both intention and recent prescribing patterns |
The Secondary First Process in Action
- Hypothesis Formation Using Secondary Data
Organizations start with integrated commercial analytics sets, mining claims, EHRs, and promotion data to:- Surface regional or practice-level anomalies (e.g., delayed therapy initiation, differential patient persistence)
- Quantify access barriers and copay patterns at the provider and patient level
- Map prescriber, patient, and payer dynamics for more precise segmentation
- Targeted, Segment-Specific Primary Research
Rather than broad, generic surveys, companies design focused research for:- High-opportunity but low-utilizing prescribers
- Practices with unique patient demographics (e.g., high dual-eligible Medicare/Medicaid mixes)
- Areas with anomalous patterns (e.g., outlier switch/add-on behavior)
- Holistic Integration and Interpretation
- Combine “what they do” (claims/behavioral data) with “what they say” (primary research) for 360° context.
- Cross-validate findings to ensure strategies align with both reality and stakeholder perspectives.
- Actionable Analytics and Execution
- Custom-tailor messaging, field activity, and payer strategies by physician or region
- Prioritize market access efforts where true systemic barriers—not just perceptions—exist
Real-World Examples
Patient Subsidy and Market Messaging
Secondary data revealed stark regional differences in patient access to a cardiovascular brand. In Miami, physicians mainly had patients with a “Low Income Subsidy” who incurred minimal copays, whereas in Sarasota, out-of-pocket costs posed access challenges. This guided the field team to deploy tailored access and messaging strategies in each city.
Delayed Add-On Therapy
Analysis flagged a set of HCPs slow to prescribe adjunctive branded therapies. Primary research identified local practice norms (peer-influenced guidance) as the real reason, redirecting tactical education to institutional rather than individual levels.
Segmenting for Action
Physician profiling through commercial analytics enabled the brand to deploy co-pay and support programs differentially, targeting needs rather than a one-size-fits-all approach, thereby maximizing impact and ROI.
Economic and Managerial Impact
| Traditional Primary ATU | Secondary First / Integrated ATU |
|---|---|
| $6–7M spend per annum for broad studies | 30–50% net cost savings via focused, iterative research |
| Repetitive, large-scale surveys | Segment-led, hypothesis-driven research |
| “Less with less”: fewer respondents, fewer insights as costs are cut | “More with less”: more actionable insights, less cost |
| Frequent ambiguity, slower commercial action | Faster, evidence-based decisions |
Best Practices for Implementation
- Create a fully integrated analytics set: HIPAA-compliant and de-identified, spanning patient, prescriber, payer, and promotional variables.
- Use secondary data to define hypotheses and prioritize research: Ensure every primary research project starts with clear, data-driven objectives.
- Institutionalize cross-functional collaboration: Connect data scientists, market researchers, and commercial teams for rapid insight-to-execution cycles.
- Pilot integrated approaches in brands/markets with complex stakeholder dynamics: Ideal for specialized, multi-product, or regimen-based therapies experiencing market performance gaps.
Conclusion
The integration of secondary data and primary research—anchored in a “Secondary First” philosophy—represents the new standard for market insight in the pharmaceutical industry. By leveraging the power of both robust data assets and stakeholder perspectives, organizations unlock a more nuanced, reliable, and actionable view of brand utilization decisions. This approach not only saves costs but ensures commercial strategies are aligned to real-world opportunities and challenges, empowering brands to optimize growth and outperform competitors in today’s complex market environments
Disclaimer: The views expressed in the article are those of the authors and not of the organizations they represent.
